Synucleinopathies are now recognized as major causes of dementia. The principal synucleinopathies are the overlapping clinical entities of Parkinson disease (PD), including Parkinson disease with dementia (PDD), and dementia with Lewy bodies (DLB). PDD and DLB are the most common causes of dementia after Alzheimer disease (AD). A clinical distinction between PDD and DLB, and distinguishing them from AD, is often difficult and, perhaps more importantly, the clinician encounters many situations in which it is unclear from clinical data and structural imaging whether a dementia reflects predominantly a single process or a complex one with Alzheimer changes coexisting with one or more of the other pathologies. In addition, as more specific therapies become available, it will be important to have methods to distinguish among the contributing pathological processes. The intent of this project is to use amyloid PET (PIB PET) combined with Clinical and neuropsychological evaluation, fluorodeoxyglucose (FDG) PET and dopamine transporter PET (in DLB ) to determine the contribution of amyloid deposition to dementia in PD and DLB.
The specific aims are as follows: 1) to perform PIB PET in DLB and PDD subjects that have been carefully characterized with respect to clinical features, changes on structural MRI, PD rating scales, neuropsychological performance, FDG PET and DAT PET (DLB);2) to perform PIB PET at study entry and after 3 years in PD subjects characterized at both time points with respect to clinical features, PD rating scales, changes on structural MRI, neuropsychological performance and FDG PET. The overall objectives of the project are to determine the following: 1) the contribution of beta-amyloid accumulation to the dementia in PDD and DLB;2) the role of beta-amyloid accumulation in the conversion of PD to PDD;3) the contribution of FDG, PIB PET and dopamine transporter PET, correlated with clinical evaluation, neuropsychological testing and structural imaging, to understanding the pathophysiology of dementia associated with synucleinopathies.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Research Program Projects (P01)
Project #
5P01AG025204-05
Application #
7812059
Study Section
Special Emphasis Panel (ZAG1)
Project Start
Project End
Budget Start
2009-05-01
Budget End
2010-04-30
Support Year
5
Fiscal Year
2009
Total Cost
$195,791
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Hu, Ziheng; Wang, Lirong; Ma, Shifan et al. (2018) Synergism of antihypertensives and cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (N Y) 4:542-555
Zhao, Yujing; Tudorascu, Dana L; Lopez, Oscar L et al. (2018) Amyloid ? Deposition and Suspected Non-Alzheimer Pathophysiology and Cognitive Decline Patterns for 12 Years in Oldest Old Participants Without Dementia. JAMA Neurol 75:88-96
Jansen, Willemijn J; Ossenkoppele, Rik; Tijms, Betty M et al. (2018) Association of Cerebral Amyloid-? Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry 75:84-95
Wilckens, Kristine A; Tudorascu, Dana L; Snitz, Beth E et al. (2018) Sleep moderates the relationship between amyloid beta and memory recall. Neurobiol Aging 71:142-148
Minhas, Davneet S; Price, Julie C; Laymon, Charles M et al. (2018) Impact of partial volume correction on the regional correspondence between in vivo [C-11]PiB PET and postmortem measures of A? load. Neuroimage Clin 19:182-189
Yan, Qi; Nho, Kwangsik; Del-Aguila, Jorge L et al. (2018) Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. Mol Psychiatry :
La Joie, Renaud; Ayakta, Nagehan; Seeley, William W et al. (2018) Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimers Dement :
Cohen, Ann D; McDade, Eric; Christian, Brad et al. (2018) Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition. Alzheimers Dement 14:743-750
Marquié, Marta; Normandin, Marc D; Meltzer, Avery C et al. (2017) Pathological correlations of [F-18]-AV-1451 imaging in non-alzheimer tauopathies. Ann Neurol 81:117-128
Mi, Zhiping; Abrahamson, Eric E; Ryu, Angela Y et al. (2017) Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. Neurobiol Aging 55:159-166

Showing the most recent 10 out of 106 publications